MAVYRET

At a glance

Key dates

1. Approval

   FDA approval date of this drug product.

   Aug 03, 2017

   9 yr ago

2. Exclusivity ends · ODE-232

   Orphan-drug exclusivity (7 years)

   Apr 30, 2026

   2 mo ago

3. Exclusivity ends · ODE-233

   Orphan-drug exclusivity (7 years)

   Apr 30, 2026

   2 mo ago

4. Today

5. Exclusivity ends · PED

   Pediatric exclusivity (adds 6 months)

   Oct 30, 2026

   in 4 mo

6. Exclusivity ends · PED

   Pediatric exclusivity (adds 6 months)

   Oct 30, 2026

   in 4 mo

7. Exclusivity ends · I-967

   New indication exclusivity (3 years)

   Jun 10, 2028

   in 2 yr

8. Exclusivity ends · ODE-372

   Orphan-drug exclusivity (7 years)

   Jun 10, 2028

   in 2 yr

9. Exclusivity ends · PED

   Pediatric exclusivity (adds 6 months)

   Dec 10, 2028

   in 2 yr 6 mo

10. Patent 10028937 expires

    Listed method-of-use patent (U-4206) expiration.

    Jun 10, 2030

    in 4 yr

11. Patent 10028937 expires

    Listed method-of-use patent (U-2141) expiration.

    Jun 10, 2030

    in 4 yr

12. Patent 10028937 expires

    Listed method-of-use patent (U-3237) expiration.

    Jun 10, 2030

    in 4 yr

13. Patent 10039754 expires

    Listed method-of-use patent (U-2141) expiration.

    Jun 10, 2030

    in 4 yr

14. Patent 10039754 expires

    Listed method-of-use patent (U-4206) expiration.

    Jun 10, 2030

    in 4 yr

15. Patent 10039754 expires

    Listed method-of-use patent (U-3237) expiration.

    Jun 10, 2030

    in 4 yr

16. Patent 9586978 expires

    Listed method-of-use patent (U-4206) expiration.

    Nov 06, 2030

    in 4 yr 5 mo

17. Patent 9586978 expires

    Listed method-of-use patent (U-3237) expiration.

    Nov 06, 2030

    in 4 yr 5 mo

18. Patent 9586978 expires

    Listed method-of-use patent (U-2141) expiration.

    Nov 06, 2030

    in 4 yr 5 mo

19. Patent 10028937*PED expires

    Listed listed patent expiration.

    Dec 10, 2030

    in 4 yr 7 mo

20. Patent 10039754*PED expires

    Listed listed patent expiration.

    Dec 10, 2030

    in 4 yr 7 mo

21. Patent 9586978*PED expires

    Listed listed patent expiration.

    May 06, 2031

    in 4 yr 11 mo

22. Patent 8648037 expires

    Listed drug substance patent expiration.

    Jan 19, 2032

    in 5 yr 8 mo

23. Patent 8648037 expires

    Listed drug substance patent expiration.

    Jan 19, 2032

    in 5 yr 8 mo

24. Patent 8648037 expires

    Listed drug substance patent expiration.

    Jan 19, 2032

    in 5 yr 8 mo

25. Patent 8937150 expires

    Listed drug substance patent expiration.

    May 18, 2032

    in 6 yr

26. Patent 8648037*PED expires

    Listed listed patent expiration.

    Jul 19, 2032

    in 6 yr 2 mo

27. Patent 8937150*PED expires

    Listed listed patent expiration.

    Nov 18, 2032

    in 6 yr 6 mo

28. Patent 10286029 expires

    Listed method-of-use patent (U-4206) expiration.

    Mar 14, 2034

    in 7 yr 10 mo

29. Patent 10286029 expires

    Listed method-of-use patent (U-3237) expiration.

    Mar 14, 2034

    in 7 yr 10 mo

30. Patent 11484534 expires

    Listed method-of-use patent (U-4206) expiration.

    Mar 14, 2034

    in 7 yr 10 mo

31. Patent 11484534 expires

    Listed method-of-use patent (U-3237) expiration.

    Mar 14, 2034

    in 7 yr 10 mo

32. Patent 10286029*PED expires

    Listed listed patent expiration.

    Sep 14, 2034

    in 8 yr 4 mo

33. Patent 11484534*PED expires

    Listed listed patent expiration.

    Sep 14, 2034

    in 8 yr 4 mo

34. Patent RE48923 expires

    Listed drug substance patent expiration.

    May 08, 2035

    in 9 yr

35. Patent 9321807 expires

    Listed drug substance patent expiration.

    Jun 05, 2035

    in 9 yr 1 mo

36. Patent RE48923*PED expires

    Listed listed patent expiration.

    Nov 08, 2035

    in 9 yr 6 mo

37. Patent 9321807*PED expires

    Listed listed patent expiration.

    Dec 05, 2035

    in 9 yr 7 mo

38. Patent 11246866 expires

    Listed drug product patent expiration.

    Jun 24, 2036

    in 10 yr 2 mo

39. Patent 11246866*PED expires

    Listed listed patent expiration.

    Dec 24, 2036

    in 10 yr 8 mo

Pharmaceutical detail

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

• MAVYRETBrand (NDA)

  NDA 215110 · ABBVIE

  2021

Marketing exclusivity (7)

• ODE-232Orphan-drug exclusivity (7 years)

  Apr 30, 2026

  2 mo ago

• ODE-233Orphan-drug exclusivity (7 years)

  Apr 30, 2026

  2 mo ago

• PEDPediatric exclusivity (adds 6 months)

  Oct 30, 2026

  in 4 mo

• PEDPediatric exclusivity (adds 6 months)

  Oct 30, 2026

  in 4 mo

• I-967New indication exclusivity (3 years)

  Jun 10, 2028

  in 2 yr

• ODE-372Orphan-drug exclusivity (7 years)

  Jun 10, 2028

  in 2 yr

• PEDPediatric exclusivity (adds 6 months)

  Dec 10, 2028

  in 2 yr 6 mo

Listed patents (30)